NASDAQ:INDP

Indaptus Therapeutics Q2 2026 Earnings Results & Report

Indaptus Therapeutics logo
$2.82 -0.31 (-9.90%)
Closing price 04:00 PM Eastern
Extended Trading
$2.82 0.00 (0.00%)
As of 05:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Indaptus Therapeutics beat analyst earnings expectations in its Q2 2026 results, released August 13, 2026. The company reported EPS of -$0.02 versus the -$1.57 consensus estimate.

Earnings Announcement Details

Quarter
Q2 2026
Report Date
Time
Before Market Opens
Conference Call
7:00 AM ET

Indaptus Therapeutics EPS Results

Actual EPS
-$0.02
Consensus EPS
-$1.57
Beat/Miss
Beat by +$1.55
One Year Ago EPS
N/A
EPS Beat Rate
7 of last 8 quarters

Indaptus Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Indaptus Therapeutics Q2 2026 Earnings FAQ

Indaptus Therapeutics (NASDAQ:INDP) reported earnings of -$0.02 per share for Q2 2026, beating the consensus estimate of -$1.57. The report was announced on Thursday, August 13, 2026.

Indaptus Therapeutics Earnings Headlines

URGENT: If you own a home, please review the map below.
More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards urges homeowners to check the map and see whether one is near them. Families in Georgia have been forced to sell, entire Ohio neighborhoods are being torn down, and nearly 50,000 Lake Tahoe residents face losing power. Rickards advised the Pentagon and the U.S. intelligence community for decades. He says one man outside Washington can stop it.tc pixel
See More Indaptus Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Indaptus Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Indaptus Therapeutics and other key companies, straight to your email.

About Indaptus Therapeutics

Indaptus Therapeutics (NASDAQ:INDP) is a clinical-stage biotechnology company developing immunotherapies intended to stimulate the immune system to fight cancer and infectious diseases. Its approach uses proprietary bacterial-based candidates designed to activate multiple immune pathways.

The company’s lead candidate, Decoy20, is an investigational immunotherapy made from a mixture of inactivated, non-pathogenic bacteria. Indaptus is evaluating the candidate in clinical research for advanced solid tumors; it has not been established as a treatment for any disease.

Indaptus is focused on developing its pipeline rather than marketing approved products. The company is headquartered in the United States, and its publicly described clinical work has included U.S. research sites.

View Indaptus Therapeutics Profile